GRAL GRAIL, Inc.
GRAL GRAIL, Inc.
Healthcare · Diagnostics & Research
Desk view
Market read
Scan convergence 2 scans as of 2026-10-16 1 bull 1 neutral converging
POC $49.31 · VWAP $79.04 · +49.0% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 1 other sold $7.3M, Oct 7–16
Coverage
2 watchlists
GRAL Price Structure
Loading timeframes…
Peers
Every watchlist GRAL belongs to, members best 30-day change first — GRAL highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-scan
@monster-discoveries
Against street estimates
How GRAL's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about GRAL from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
GRAL research tape
35 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.